2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 936

Reliability and Responsiveness of an Omeract Tenosynovitis Magnetic Resonance Imaging Scoring System for the Rheumatoid Arthritis Wrist and Hand
Abstract Number: 1261

Reliability and Validity of the Patient Health Questionnaire-9 for Assessment of Depression in Socioeconomically Disadvantaged Latinos with Rheumatoid Arthritis Living in the United States
Abstract Number: 139

Reliability of Ultrasound in Detecting Cartilage Change in Patients with Rheumatoid Arthritis: A Study By Omeract Ultrasound Task Force
Abstract Number: 1888

Reliability, Validity, and Sensitivity to Change of the Simplified Duruoz Hand Index in Systemic Sclerosis
Abstract Number: 2466

Remission According to RAPID3 (routine assessment of patient index data 3) in Patients with Rheumatoid Arthritis: A Cross-Sectional 3 Center Study from Routine Care
Abstract Number: 1779

Remission and Low Lupus Disease Activity Status (LLDAS) Protect Lupus Patients from Damage Occurrence: Data from a Multi-Ethnic, Multinational Latin American Lupus Cohort
Abstract Number: 3147

Remote Inflammation Triggers Autoimmune Arthritis through Th17 Distribution
Abstract Number: 966

Renal Activity in Lupus (RAIL) Urinary Biomarkers Predict Treatment Response
Abstract Number: 206

Renal Safety of Lesinurad: A Pooled Analysis of Phase III and Extension Studies
Abstract Number: 443

Repetitive Requisition of Antinuclear Antibody Testing (ANA) in Outpatient Multispecialty Clinics in Patients with a Known Positive ANA
Abstract Number: 120

Reproductive Tract Infections (RTI) in Indian (Asian) Women of Child Bearing Age Suffering from RA:I Don’t Ask Them, They Don’t Tell Me
Abstract Number: 459

Resident Non-Classical Monocytes Are Critically Important for Tissue Destruction in Arthritis
Abstract Number: 2659

Respiratory Symptoms in Patients with Primary SjöGren’s Syndrome – a Case-Control Study
Abstract Number: 1358

Response of Hidradenitis Suppurativa to Biologic Therapy
Abstract Number: 769

Response to Belimumab in SLE Patients with High Disease Activity: Data from a Multicentric Clinical-Practice Based Study Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].